Catherine Reed

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease?
    Catherine Reed
    Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Health Qual Life Outcomes 15:16. 2017
  2. pmc Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer's disease: a retrospective, matched case-control study in the United Kingdom
    Lei Chen
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN 46285, USA
    BMC Geriatr 14:76. 2014
  3. pmc Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database
    Catherine Reed
    Global Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK
    Clinicoecon Outcomes Res 5:37-47. 2013
  4. pmc Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication
    Jean Michel Azorin
    Neurosciences Medical department, Eli Lilly and Company, Suresnes, France
    BMC Psychiatry 9:33. 2009
  5. doi request reprint Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER
    Catherine Reed
    Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham, Surrey, UK
    J Affect Disord 113:296-302. 2009
  6. doi request reprint Observational study designs for bipolar disorder - what can they tell us about treatment in acute mania?
    Catherine Reed
    Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, GU20 6PH, UK
    Prog Neuropsychopharmacol Biol Psychiatry 33:715-21. 2009
  7. doi request reprint Work impairment in bipolar disorder patients--results from a two-year observational study (EMBLEM)
    C Reed
    Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, Windlesham GU20 6PH, UK
    Eur Psychiatry 25:338-44. 2010
  8. pmc How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study
    Mark Belger
    Lilly Research Centre, Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham Surrey, GU20 6PH, UK
    BMC Med Res Methodol 16:83. 2016
  9. doi request reprint Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease
    Catherine Reed
    Global Health Outcomes, Lilly Research Centre, Eli Lilly and Company Limited, Windlesham, Surrey, UK
    Int Psychogeriatr 28:247-59. 2016
  10. doi request reprint Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice
    Diego Novick
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 25:257-63. 2010

Detail Information

Publications16

  1. pmc How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease?
    Catherine Reed
    Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
    Health Qual Life Outcomes 15:16. 2017
    ....
  2. pmc Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer's disease: a retrospective, matched case-control study in the United Kingdom
    Lei Chen
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN 46285, USA
    BMC Geriatr 14:76. 2014
    ..This study examined medical resource utilisation patterns in the United Kingdom (UK) prior to and following Alzheimer's disease (AD) diagnosis...
  3. pmc Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database
    Catherine Reed
    Global Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK
    Clinicoecon Outcomes Res 5:37-47. 2013
    ..To assess the impact of pain severity and time to diagnosis of depression on health care costs for primary care patients with pre-existing unexplained pain symptoms who subsequently received a diagnosis of depression...
  4. pmc Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication
    Jean Michel Azorin
    Neurosciences Medical department, Eli Lilly and Company, Suresnes, France
    BMC Psychiatry 9:33. 2009
    ..To describe the clinical course and treatment patterns over 24 months of patients experiencing an acute manic/mixed episode within the standard course of care...
  5. doi request reprint Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER
    Catherine Reed
    Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham, Surrey, UK
    J Affect Disord 113:296-302. 2009
    ..We studied the impact of antidepressant (AD) treatment on HRQoL outcomes in depressed patients and investigated factors associated with these outcomes in routine practice settings...
  6. doi request reprint Observational study designs for bipolar disorder - what can they tell us about treatment in acute mania?
    Catherine Reed
    Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, GU20 6PH, UK
    Prog Neuropsychopharmacol Biol Psychiatry 33:715-21. 2009
    ..4%) and week 12 (50.5%). The results of this observational study show that treatment for mania is complex with multiple combinations of treatment and frequent switching during an acute episode...
  7. doi request reprint Work impairment in bipolar disorder patients--results from a two-year observational study (EMBLEM)
    C Reed
    Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, Windlesham GU20 6PH, UK
    Eur Psychiatry 25:338-44. 2010
    ..To explore factors associated with work impairment at 2 years following an acute episode...
  8. pmc How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study
    Mark Belger
    Lilly Research Centre, Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham Surrey, GU20 6PH, UK
    BMC Med Res Methodol 16:83. 2016
    ..We aimed to evaluate the effects of different methods for dealing with missing longitudinal cost data and for costing caregiver time on total societal costs in Alzheimer's disease (AD)...
  9. doi request reprint Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease
    Catherine Reed
    Global Health Outcomes, Lilly Research Centre, Eli Lilly and Company Limited, Windlesham, Surrey, UK
    Int Psychogeriatr 28:247-59. 2016
    ..We aimed to obtain a better understanding of how different aspects of patient functioning affect key cost and caregiver outcomes in Alzheimer's disease (AD)...
  10. doi request reprint Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice
    Diego Novick
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 25:257-63. 2010
    ..Limitations include differences in study design, patient population, and length of follow-up...
  11. pmc Incidence of diabetic peripheral neuropathic pain in primary care - a retrospective cohort study using the United Kingdom General Practice Research Database
    Catherine Reed
    Global Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK
    Pragmat Obs Res 4:27-37. 2013
    ..To determine the incidence of diabetic peripheral neuropathic pain (DPNP) in the United Kingdom (UK) primary care population using the General Practice Research Database (GPRD)...
  12. pmc Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study
    Alan Lenox-Smith
    Eli Lilly and Company, Basingstoke, UK
    BMC Geriatr 16:195. 2016
    ..Alzheimer's disease (AD), the commonest cause of dementia, represents a significant cost to UK society. This analysis describes resource utilisation, costs and clinical outcomes in non-institutionalised patients with AD in the UK...
  13. doi request reprint Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis
    Inge van Rossum
    Medical Department, Eli Lilly Nederland, Houten, The Netherlands
    J Nerv Ment Dis 197:35-40. 2009
    ..An independent impact of cannabis use on psychopathologic outcomes in patients with bipolar disorder was apparent, whereas the impact on social outcomes was modest...
  14. doi request reprint Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics, London, UK
    Psychiatry Res 190:110-4. 2011
    ..05). In conclusion, non-adherence in bipolar patients was associated with poorer long term clinical outcomes that have economic implications for health-care providers...
  15. doi request reprint Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics and Political Science, London, United Kingdom
    Spine (Phila Pa 1976) 38:75-82. 2013
    ..Retrospective cohort study of health care costs associated with the treatment of chronic low back pain (CLBP) in the United Kingdom...